Table 3 Treatments received by patients in the previous 24 months.
| NV‐AMD treatment | Past 12 months | Past 13–24 months | ||
|---|---|---|---|---|
| Better eye | Worse eye | Better eye | Worse eye | |
| Verteporfin, n (%) | 15 (20.0) | 4 (5.3) | 7 (9.3) | 6 (8.0) |
| Mean (SD) number of treatments* | 1.1 (0.3) | 2.0 (0.7) | 1.2 (0.4) | 1.5 (1.2) |
| Simultaneous verteporfin treatment in both eyes, n (%) | 2 (2.7) | 1 (1.3) | ||
| Mean (SD) number of treatments* | 1.0 (0.0) | 1.0 (n/a) | ||
| IVT corticosteroids | 4 (5.3) | 1 (1.3) | 1 (1.3) | 0 (0.0) |
| Mean (SD) number of treatments* | 1.3 (0.5) | 1.0 (n/a) | 1.0 (n/a) | n/a |
| PDT with IVT corticosteroids | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
IVT, intravitreal; NV‐AMD = neovascular age‐related macular degeneration; PDT, photodynamic therapy; SD = standard deviation.
*Among subjects who received the treatment.